Biogen to Acquire Reata for US$7.3 B for Rare Disease Portfolio
By Lalit Mishra
Pharma Deals Review: Vol 2023 Issue 8 (Table of Contents)
Published: 1 Aug-2023
DOI: 10.3833/pdr.v2023.i8.2797 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a significant move towards bolstering the rare disease portfolio, Biogen has agreed to acquire Reata Pharmaceuticals for US$172...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS